Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Norin, Stefan; Björkstrand, Bo; Rommel, Franz; Timberg, Lars; Andersson, Per-Ola; Häggström, Johan; Aldrin, Anders; Hansson, Lotta
• Is Part Of: Leukemia research. Volume 39:Issue 1(2015:Jan.)
• Page Start: 33
• Page End: 37
• Publication Date: 2015-01
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2014.09.019
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">There have been concerns about infusion-related reactions with rituximab in CLL.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">We conducted an observational trial to study infusion-related adverse events.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Severe events occurred in 5%, which in line with published randomized trials.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Rituximab-containing CLL regimens can be considered safe in general practice.</p> </list-item> </list> </p> </sec> </abstract>